Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:0IT Stock Latest News

Company AnnouncementsSatellos Bioscience Forms Scientific Advisory Board to Expand Regeneration and Neuroscience Research6d ago6K MSLE

Company AnnouncementsSatellos Bioscience to Court Investors at November Healthcare Conferences1w ago6K MSLE
The FlySatellos management to meet with Cantor3w agoMSLE
The FlyCraig-Hallum initiates Satellos with a Buy ahead of BASECAMP data3w agoMSLE
The FlySatellos initiated with a Buy at Craig-Hallum3w agoMSLE

Satellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin

Company AnnouncementsSatellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin4w ago6K MSLE

The FlySatellos granted composition of matter patent for forazapadin4w agoMSLE

RatingsAnalyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress1M agoMSLE

Company AnnouncementsSatellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular Dystrophy1M ago6K MSLE
The FlySatellos announces enrollment completed for BASECAMP1M agoMSLE
RatingsSatellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $221M agoMSLE
Company AnnouncementsSatellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding1M agoMSLE

Satellos announces U.S. FDA cleared IND application for forazapadin

The FlySatellos announces U.S. FDA cleared IND application for forazapadin1M agoMSLE

Company AnnouncementsSatellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress1M ago6K MSLE

Company AnnouncementsSatellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance1M ago6K MSLE

The FlySatellos assigns forazapadin name to SAT-32471M agoMSLE
Company AnnouncementsSatellos Bioscience to Showcase DMD Drug Program at September Investor Conferences2M ago6K MSLE
RatingsBuy Rating on Satellos Bioscience Highlights Transformative Potential of First-in-Class Oral DMD Therapy Ahead of Key 4Q26 Phase 2 Readouts2M agoMSLE
The FlySatellos initiated with an Outperform at LifeSci Capital2M agoMSLE

Satellos: Buy Rating Reiterated as Phase 2 Progress Advances and $18 Price Target Remains Unchanged

RatingsSatellos: Buy Rating Reiterated as Phase 2 Progress Advances and $18 Price Target Remains Unchanged2M agoMSLE

Company AnnouncementsSatellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility2M ago6K MSLE

Company AnnouncementsSatellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base2M ago6K MSLE